MHRA Proposes New Regulatory Pathway for Rare Disease Therapies
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on a new, technology‑agnostic regulatory pathway for rare disease therapies. Central to the proposal is an Investigational Marketing Authorisation (IMA) that merges clinical trial approval with a progressive route to marketing authorisation, allowing rolling data submissions and modular assessments. The framework encourages adaptive trial designs, real‑world evidence, surrogate endpoints and digital‑twin modelling to overcome scientific and commercial barriers. The consultation runs until 30 July and seeks input from pharma, biotech, clinicians, patients and other stakeholders.
Infex Reports Phase IIa Win for Anti-Pseudomonas Antibody
Infex Therapeutics announced positive Phase IIa results for RESP‑X, its first‑in‑class anti‑virulence monoclonal antibody targeting PcrV in Pseudomonas‑colonised non‑cystic fibrosis bronchiectasis. The randomized, double‑blind trial demonstrated safety, tolerability and a 28.8‑day half‑life supporting quarterly dosing. While the study was not powered...
Eli Lilly Acquires Engage Biologics for ~$202M
Eli Lilly announced the acquisition of Engage Biologics for roughly $202 million in cash, integrating Engage’s Tethosome non‑viral DNA delivery platform with Lilly’s growing genetic‑medicine portfolio. The deal includes an upfront payment and milestone‑based earn‑outs tied to development progress. Tethosome combines engineered DNA...
Genetic Insights From 619,372 Metabolic Profiles
A landmark study examined 619,372 metabolic profiles linked to genetic data, creating the largest metabolomics‑genomics dataset to date. Researchers uncovered more than 1,200 genetic loci that modulate circulating metabolite concentrations, many of which map to pathways implicated in cardiometabolic disease....
The Next Era of Healthcare Is Personal
In this episode, McKinsey’s Eric Kutcher talks with Moderna CEO Stéphane Bancel about how mRNA technology and AI are reshaping healthcare from rapid vaccine development to truly personalized medicines. Bancel explains that mRNA is an "information molecule" that can be programmed...
Targeting Inflammation in Depression: A Proof-of-Concept Worth Following
A proof‑of‑concept randomized trial examined a single intravenous dose of tocilizumab, an IL‑6 receptor blocker, in 29 adults with treatment‑resistant major depressive disorder and low‑grade inflammation (CRP ≥ 3 mg/L). The drug safely reduced CRP levels, but the primary outcome—somatic depression symptoms—did not...
Imperagen Raises £5 Million to Use Quantum Physics, AI on Enzyme Engineering
Imperagen, a Manchester‑spun biotech founded in 2021, closed a $6.7 million seed round led by PXN Ventures, bringing total funding to $11.42 million. The startup combines quantum‑physics simulations, custom AI models, and robotic closed‑loop experimentation to accelerate enzyme engineering. It aims to...
Algae‑Powered Robot Swarms Heal Wounds Using Light
Living #Robot swarms built from algae can split, merge, and target wounds with light by Neetika Walter @IntEngineering Learn more: https://t.co/eFL1uXG9hg #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/P2jlormizm
Lantern Pharma Gets FDA Type C Clearance for LP-300 Phase 2 Trial in Never‑Smoker NSCLC
Lantern Pharma announced that the FDA issued a successful Type C meeting response, clearing protocol amendments for its LP-300 Phase 2 HARMONIC trial. The agency raised no objections to focusing enrollment on EGFR exon 21 L858R‑mutant never‑smokers and extending treatment...
Flatiron Health Launches AI Platform Flatiron Telescope to Deliver Oncology Insights in Minutes
Flatiron Health introduced Flatiron Telescope, an AI-powered platform that generates oncology insights in minutes, leveraging data from over 5 million patient journeys. The tool promises to cut study feasibility timelines from months to minutes, offering real‑time cohort building and analytics for...
Achieve Life Sciences Presents 52‑Week Cytisinicline Safety Data Ahead of FDA Decision
Achieve Life Sciences disclosed 52‑week safety results from its ORCA‑OL trial of Cytisinicline, a nicotine‑dependence therapy, at the ATS 2026 meeting. The data reinforce long‑term tolerability as the company approaches a June 20, 2026 FDA PDUFA deadline for its New...
Did a Boy’s Life-Saving Gene Therapy Cause His Brain Tumour?
A five‑year‑old who received adeno‑associated virus (AAV) gene therapy for a rare genetic disorder developed a brain tumor four years later. Genetic analysis traced the tumor to integration of the viral vector into the child’s genome, suggesting a causal link....
Atyr Pharma Launches Global Phase 3 Trial C-006 of Efzofitimod for Pulmonary Sarcoidosis
Atyr Pharma announced the start of a global Phase 3 trial (C-006) of its anti‑inflammatory drug efzofitimod in pulmonary sarcoidosis, prioritizing forced vital capacity as the primary endpoint. The move follows a Type C meeting with the FDA that reshaped...
Surveillance: Post Drug-Approval Activities
The FDA’s Center for Drug Evaluation and Research (CDER) oversees post‑marketing surveillance to ensure that drugs remain safe and effective after approval. Through mandatory adverse‑event reporting and targeted monitoring programs, the agency can identify unexpected risks. When serious concerns arise,...
GLP-1s Show Promise for Glaucoma, AMD, Other Eye Diseases
GLP‑1 receptor agonists, long used for diabetes and obesity, are emerging as potential treatments for several eye conditions. Recent reviews cite modest reductions in intra‑ocular pressure and lower incidence of primary open‑angle glaucoma among users. The data on diabetic retinopathy...
Eton Pharmaceuticals Secures U.S. Rights to IMPAVIDO, Adds 2026 Leishmaniasis Launch
Eton Pharmaceuticals announced an exclusive U.S. commercialization agreement for IMPAVIDO, the only FDA‑approved oral treatment for multiple forms of leishmaniasis, with rights effective Sept. 26, 2026. The deal adds a new 2026 launch to Eton’s rare‑disease pipeline and is tied to a...
Collaborative Drug Discovery Inks Deal with Eli Lilly to Accelerate Biotech Innovation
Eli Lilly’s TuneLab AI platform will be embedded into Collaborative Drug Discovery’s (CDD) Vault system, giving biotech companies access to Lilly’s proprietary ADMET predictive models. The integration will appear in both the core and AI modules of CDD Vault, allowing researchers...
HELIX AI Model Accurately Predicts RNA Splicing, Unlocks Precision Medicine
Researchers at the Chinese Academy of Sciences unveiled HELIX, an AI framework that predicts RNA splicing and isoform usage with unprecedented accuracy. By combining DNA sequence data with expression profiles of 1,499 RNA‑binding proteins, the model outperforms existing tools across...
Abbreviated New Drug Application (ANDA)
On October 3, 2025, the FDA unveiled a pilot program that fast‑tracks the review of abbreviated new drug applications (ANDAs) submitted by generic manufacturers that test and produce their products in the United States. The initiative is designed to spur...
Longevity Biotech Matures: Precise Indication‑Focused Drug Development
The longevity biotechnology field is coming of age in the best possible way. A recent analysis captures how the sector has learned to speak pharma’s language fluently—moving from broad claims about “slowing aging” to precise, indication-focused drug development with conventional endpoints,...
IL-6 Blocker Shows Promise for Treating Depression
Would depression respond to an anti-inflammation drug (interleukin-6 blocker)? A small pilot, placebo-controlled randomized trial suggests this might be possible https://t.co/zKO76yvRAo https://t.co/e8K9YLEAQj
STAT+: Biotech Execs, Academic Expert Lament Impact of FDA Turnover on Rare Disease Drug Development
Biotech leaders and an academic expert warned that recent turnover among senior FDA officials is creating heightened uncertainty for rare‑disease drug developers. At the STAT Breakthrough Summit West, Mahzi Therapeutics CEO Yael Weiss described constant investor inquiries and a “roller‑coaster”...
FDA Clears INTERACT Meeting for Glafabra’s Fabry Gene Therapy, Paving Way for Single‑Shot Treatment
The U.S. Food and Drug Administration accepted Glafabra Therapeutics’ request for a face‑to‑face INTERACT meeting on July 16, 2026, to discuss its lead Fabry disease gene therapy GT-GLA‑S03. The meeting, granted to only about 30% of applicants, moves the company...
FDA Clears Johns Hopkins AI Tool that Cuts Sepsis Deaths by 20%
The U.S. Food and Drug Administration gave clearance to an AI‑driven early‑warning system from Johns Hopkins University that identifies sepsis up to 48 hours before clinicians suspect it. Early data show a near‑20% reduction in sepsis‑related deaths across dozens of...
Activist Targets 80%-Down Biopharma at Cash‑Discount
Clinical-stage biopharma down 80% after a failed trial, now at a massive discount to net cash Biopharma activist just took a sizeable position via 13G. Mgmt has prior wind-down and sell experienc. Clear path: halt trial, strategic review, re-rate higher. Full pitch on...
Parabilis Raises $800M, Eyes IPO to Tackle Undruggable Targets
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets https://t.co/hKprr9rkJ4 @ByJonGardner $PBLS #biotech #IPO
Monopar's ALXN1840 Cuts Copper in Wilson Disease Phase 2 Trial
Monopar Therapeutics announced that its experimental drug ALXN1840 achieved rapid, statistically significant copper reduction in a nine‑patient Phase 2 trial for Wilson disease. The open‑label study, published in Hepatology Communications, marks a key milestone for the first‑in‑class ATC activator. The data...
Mutating Antibodies for Easier Drug-Conjugate Manufacturing
Scientists at Johns Hopkins University have engineered a general‑purpose antibody by mutating its fragment crystallizable (Fc) region, creating up to four new attachment sites for molecules such as drugs, dyes, or nanoparticles. Six precise Fc mutations enable consistent, site‑specific conjugation,...
Mixed-Reality Fermentation Simulator Preps Workforce
Mixed-reality platform BioSuite Virtual, created by Prism Immersive with BioMADE funding, delivers end‑to‑end fermentation training through over 40 interactive modules. The system blends virtual bioreactors with physical space, letting learners assemble, sterilize, inoculate, and monitor runs at their own pace....
Emerging Nanoreactors for Precision Disease Treatment: From Principles to Biomedical Applications
Nanoreactors—engineered nanostructures that emulate cellular compartments—are reshaping precision nanomedicine. By confining reactants, integrating synergistic catalytic sites, and responding to physiological cues, they dramatically accelerate therapeutic reactions and enable controlled drug release. Recent advances span organic, polymeric, and organic‑inorganic hybrids, showing...
Application of Hydrogel in the Capture and Detection of Circulating Tumor Cells
The review details how hydrogel‑based platforms are reshaping circulating tumor cell (CTC) capture and detection. Hydrogels provide a three‑dimensional porous matrix that enhances cell infiltration, biocompatibility that preserves CTC viability, and tunable chemistry for affinity‑driven targeting. By coupling these materials...
Medtronic Data Back Renal Denervation in the Long Term
Medtronic reported that two EuroPCR abstracts based on the global SYMPLICITY registry show its Symplicity Spyral renal denervation system delivers sustained blood‑pressure reductions over three years. One analysis of 787 patients with prior cardiovascular events recorded a 17.4 mmHg drop in office...
BARDA Ships Experimental Ebola Antibody to Protect High‑risk Americans
BARDA is coordinating shipment of an experimental antibody treatment for potential use in high-risk Americans exposed to #ebola, HHS tells CNN While they didn't name the treatment, Mapp's MBP134 has shown activity in animal studies against Bundibugyo strain
FDA’s Megha Kaushal ASGCT Talk: PFDD, Patient Voices, Decision-Making
At the 2026 ASGCT meeting, FDA Acting Deputy Director Megha Kaushal highlighted the agency’s Patient‑Focused Drug Development (PFDD) initiative, urging early integration of patient and caregiver input into cell and gene therapy trials. She emphasized that families’ lived‑experience data should inform...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced FDA approval of Guardant360® Liquid CDx, the largest liquid‑biopsy panel on the market, featuring a 100‑fold expanded genomic footprint. The test merges genomic and epigenomic profiling from a single blood draw, delivering several‑fold higher circulating tumor DNA...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
IntraBio announced regulatory authorization to launch its pivotal Phase III trial of levacetylleucine (AQNEURSA) in CACNA1A‑related disorders across the United States, United Kingdom, European Union and Switzerland. The 12‑week, randomized, double‑blind, placebo‑controlled crossover study will be conducted at twelve multinational sites...
WVE-006 RNA Editing Therapy Achieves MZ-Like Phenotype in Alpha-1 Antitrypsin Deficiency Phase 1b/2a Trial
Wave Life Sciences reported that its investigational RNA‑editing drug WVE‑006 generated major‑variant alpha‑1 antitrypsin (M‑AAT) levels comparable to the protective heterozygous Pi*MZ phenotype in patients with homozygous Pi*ZZ AAT deficiency. The Phase 1b/2a RestorAATion‑2 trial showed 64%–59% of circulating AAT was...
EQS-News: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
GeoVax Labs warned that the escalating Bundibugyo Ebola outbreak in Central Africa highlights the lack of licensed vaccines for less‑common Ebola strains. The company pointed to its Modified Vaccinia Ankara (MVA) platform, which has shown single‑dose protection against Zaire and...
FDA Approves Baxdrostat, First‑in‑Class Aldosterone Synthase Inhibitor for Hypertension
The U.S. Food and Drug Administration has approved baxdrostat, AstraZeneca's first‑in‑class oral aldosterone synthase inhibitor, as an add‑on treatment for adults whose hypertension remains uncontrolled despite existing therapy. The decision follows a Phase III trial that demonstrated statistically significant systolic blood‑pressure...
Ipsen’s Dysport Outlasts Botox in First Head‑to‑Head Spasticity Trial
Ipsen announced that its botulinum toxin product Dysport delivered significantly longer symptom control than rival Botox in the Phase IV DIRECTION trial, a randomized head‑to‑head study of 464 adults with upper‑limb spasticity across 72 sites in the U.S., France and Canada.
Annovis Bio Raises $175 Million in Share and Warrant Offering to Advance Alzheimer’s Drug Buntanetap
Annovis Bio disclosed a $175 million public offering of shares and warrants to finance the Phase 3 development of its Alzheimer’s candidate Buntanetap. The financing move coincided with a 5.4% drop in the company’s stock, reflecting market caution. Proceeds will support the...
Treating Pattern Hair Loss: How Close Are We?
VeraDermics’ oral minoxidil pill VDPHL01 cleared a pivotal phase 2/3 trial, showing a 30‑33 hairs/cm² increase in non‑vellus hair count versus 7.3 for placebo and coverage improvement in over 79% of participants. The extended‑release formulation reduces peak blood levels that have...
Scientists Found a Hidden Alzheimer’s Trigger and Shut It Down
Researchers at Indiana University identified the brain enzyme IDOL as a promising new target for Alzheimer’s therapy. Deleting IDOL from neurons in mouse models dramatically cut amyloid plaque buildup and lowered APOE levels, a key genetic risk factor. The findings...
Engineered Nanomaterials Optimize Delivery Barriers in Cancer Immunotherapy
A new review outlines how engineered nanomaterials can overcome delivery bottlenecks in cancer immunotherapy by matching material design to each step of the immunity cycle. It details active‑targeting ligands, intracellular escape mechanisms, and co‑delivery of antigens, adjuvants, mRNA or CRISPR...
Beam One-Ups Wave as Both Show Promise of Editing for AATD
Beam Therapeutics presented Phase 1/2 data for its DNA editor BEAM‑302, showing an 80% drop in mutated alpha‑1 antitrypsin (AAT) protein and lifting total AAT above the 11 µM protective threshold, with effects lasting 12 months. Wave Life Sciences reported its RNA editor...
AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis
UCB’s Bimzelx outperformed AbbVie’s Skyrizi in a Phase 3 head‑to‑head trial for psoriatic arthritis, achieving 49.1% ACR50 versus 38.4% for Skyrizi at week 16. While Bimzelx also showed numerically higher minimal disease activity (43% vs 39.9%), the difference missed statistical significance. Skyrizi...
Ketamine‑Buprenorphine Regimen Cuts Suicide Ideation by 76% in Trial
Researchers reported that a single ketamine infusion followed by four weeks of low‑dose buprenorphine lowered suicidal ideation by 76% in adults with major depressive disorder, far surpassing the 43% reduction seen with placebo. The double‑blind trial, published in the American...
Topical Senolytic ABT-263 Boosts Wound Healing in Aged Mice by 43%
Researchers at Boston University demonstrated that a cream containing the senolytic ABT-263 removed aging skin cells and accelerated wound repair in elderly mice, achieving an 80% healing rate by day 24 versus 56% in controls. The finding points to a...
Relay Therapeutics Posts 60% Response in Phase 2 Trial of Zovegalisib for Rare Vascular Anomalies
Relay Therapeutics said 60% of evaluable patients achieved a volumetric response in its Phase 2 ReInspire trial of zovegalisib for PIK3CA‑driven vascular anomalies. The data, presented at the ISSVA World Congress, outpace Novartis' prior 11% response and could position the...
Airway Therapeutics CEO on Rethinking Bronchopulmonary Dysplasia Trials
Airway Therapeutics is advancing zelpultide alfa, an investigational biologic aimed at preventing bronchopulmonary dysplasia (BPD) in extremely preterm infants born between 22 and 27 weeks gestation. CEO Marc Salzberg highlighted the clinical and operational hurdles of neonatal trials, including limited...